Skip to main content

Piper Sandler Remains a Buy on Legend Biotech (LEGN)

Tipranks - Tipranks - Fri Jan 16, 6:24AM CST

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Legend Biotech, with a price target of $78.00.

Claim 70% Off TipRanks Premium

Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of 2.6% and a 40.25% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $67.30 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Legend Biotech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $272.33 million and a GAAP net loss of $39.69 million. In comparison, last year the company earned a revenue of $160.21 million and had a GAAP net loss of $125.32 million

Read More on LEGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).